



WHAT IS CLAIMED IS:

1. A compound of the formula (I)




wherein R is hydrogen or alkyl and R' is selected from the group consisting of hydrogen, halo, alkyl, hydroxy, nitro, amino, alkylamino, thiocyno, isothiocyno, carboxyl, carboxyalkyl, carboxyalkyloxy, amido, alkylamido and haloalkylamido.

2. A compound of the formula (II)




wherein R is hydrogen or alkyl and R' is selected from the group consisting of hydrogen, halo, alkyl, hydroxy, nitro, amino, alkylamino, thiocyno, isothiocyno, carboxyl, carboxyalkyl, carboxyalkyloxy, amido, alkylamido and haloalkylamido.

3. The compound of claim 2 of the formula




4. A compound of the formula (III)



(III)

wherein R is hydrogen or alkyl and R' is selected from the group consisting of hydrogen, halo, alkyl, hydroxy, nitro, amino, alkylamino, thiocyno, isothiocyno, carboxyl, carboxyalkyl, carboxyalkyloxy, amido, alkylamido and haloalkylamido.

5. The compound of claim 4 of the formula



6. A complex comprising the compound of claim 1 and a metal ion, wherein the metal ion is optionally radioactive.

7. A complex comprising the compound of claim 2 and a metal ion, wherein the metal ion is optionally radioactive.
8. A complex comprising the compound of claim 3 and a metal ion, wherein the metal ion is optionally radioactive.
9. A complex comprising the compound of claim 4 and a metal ion, wherein the metal ion is optionally radioactive.
10. A complex comprising the compound of claim 5 and a metal ion, wherein the metal ion is optionally radioactive.
11. The complex of any of claims 6-10, wherein the metal ion is selected from the group consisting of Bi, Pb, Y, Mn, Cr, Fe, Co, Ni, Tc, In, Ga, Cu, Re, Sm, a lanthanide, and an actinide.
12. The complex of claim 11, wherein the lanthanide is Gd(III).
13. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound of any of claims 1-5.
14. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the complex of any of claims 6-10.
15. A method for diagnostic imaging of a host, which method comprises:
 - (i) administering to the host the complex of any of claims 6-10 in an amount effective to provide an image; and
 - (ii) exposing the host to an energy source, whereupon a diagnostic image of the host is obtained.
16. A method for magnetic resonance imaging of a host, which method comprises:
 - (i) administering to the host the complex of any of claims 6-10, in which the metal ion is paramagnetic, in an amount effective to provide an image; and
 - (ii) exposing the host to a magnet, whereupon a magnetic resonance image of the host is obtained.

17. The method of claim 16, wherein the complex comprises Gd.
18. A method for x-ray imaging of a host, which method comprises:
- (i) administering to the host the complex of any of claims 6-10, in which the metal ion is radio-opaque, in an amount effective to provide an image; and
 - (ii) exposing the host to x-rays, whereupon an x-ray contrast image of the host is obtained.
19. The method of claim 18, wherein the complex comprises ^{213}Bi , ^{212}Bi , ^{212}Pb , ^{225}Ac , ^{177}Lu , $^{99\text{m}}\text{Tc}$, ^{111}In , ^{11}C , ^{13}N , ^{123}I , ^{186}Re , ^{18}F , ^{15}O , ^{201}Tl , ^3He , ^{166}Ho or ^{67}Ga .
20. A method for single photon emission computed spectroscopy (SPECT) imaging, which method comprises:
- (i) administering to the host the complex of any of claims 6-10, in which the metal emits a single photon, in an amount effective to provide an image; and
 - (ii) exposing the host to an energy source, whereupon a SPECT image of the host is obtained.
21. The method of claim 20, wherein the complex comprises ^{213}Bi , ^{212}Bi , ^{212}Pb , ^{225}Ac , ^{177}Lu , $^{99\text{m}}\text{Tc}$, ^{111}In , ^{11}C , ^{13}N , ^{123}I , ^{186}Re , ^{18}F , ^{15}O , ^{201}Tl , ^3He , ^{166}Ho or ^{67}Ga .
22. A method for treating a cellular disorder in a mammal, which method comprises administering to the mammal the complex of any of claims 6-10 in an amount effective to treat the cellular disorder, whereupon the cellular disorder in the mammal is treated.
23. The method of claim 22, wherein the complex comprises ^{90}Y , ^{213}Bi , ^{212}Bi , ^{212}Pb or ^{225}Ac .
24. The method of claim 22, wherein the cellular disorder is cancer.
25. The method of claim 24, wherein the complex comprises ^{90}Y , ^{213}Bi , ^{212}Bi , ^{212}Pb or ^{225}Ac .

26. A conjugate comprising the complex of any of claims 6-10 and a biomolecule.

27. The conjugate of claim 26, wherein the biomolecule is selected from the group consisting of a hormone, an amino acid, a peptide, a peptidomimetic, a protein, deoxyribonucleic acid (DNA), ribonucleic acid (RNA), a lipid, an albumin, a polyclonal antibody, a receptor molecule, a receptor binding molecule, a hapten, a monoclonal antibody and an aptamer.